Heat Biologics Inc. | Mutual Funds
Mutual Funds that own Heat Biologics Inc.
Vanguard Total Stock Market Index Fund
366,360
1.59%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
245,247
1.06%
8,800
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
95,762
0.41%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
31,911
0.14%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
27,222
0.12%
0
0%
07/31/2018
Vanguard Balanced Index Fund
22,756
0.1%
0
0%
07/31/2018
DFA US Targeted Value Portfolio
14,398
0.06%
14,398
0%
04/30/2018
DFA US Small Cap Portfolio
10,280
0.04%
10,280
0%
04/30/2018
5,918
0.03%
0
0.04%
09/05/2018
Vanguard Total Stock Market Index Trust
4,711
0.02%
0
0%
07/31/2018
| Address |
801 Capitola Drive
Durham North Carolina 27713
United States
|
|
Employees
|
- |
| Website |
http://www.heatbio.com |
| Updated |
07/08/2019 |
| Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. |
